You value biotechs at 6 times sales conservatively. Gattex and Natpara are both $1 billion drugs. Sensipar is going to add a few hundred million before it comes off patent. So, 6 x $2 billion is $12 billion plus $400 million from Sensipar gives you $12.4 billion market cap in about 4 years. Throw in the rest of the pipeline for free.
you want investors to wait 4 years dumb person.
first of it is not 6x but 4x
secondly it is orphan and ultra orphan which means sales are not consistent
thirdly NPSP already sitting over $4B
even if you go by your valuation $12B
that means 34 x 3x = $102
the only way for NPSP is acquire something like DARA or how GALE did
WoW... flex those mucsles.. if u wanna reply to a fellow investors postdont be a #$%$
Valuation is built in to the price already but we are waiting on a few good things to happen soon. Nps raised guidance last quarter and the stock slipped giving longs another great buying opportunity. This company is on the rebound and well run... not one to short. Good luck researching.